Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 8.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,765 shares of the company’s stock after acquiring an additional 226 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Medpace were worth $669,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in MEDP. Handelsbanken Fonder AB boosted its holdings in Medpace by 46.9% during the second quarter. Handelsbanken Fonder AB now owns 4,700 shares of the company’s stock worth $1,129,000 after buying an additional 1,500 shares in the last quarter. Chase Investment Counsel Corp boosted its holdings in Medpace by 3.2% during the third quarter. Chase Investment Counsel Corp now owns 9,849 shares of the company’s stock worth $2,384,000 after buying an additional 301 shares in the last quarter. Atria Investments Inc acquired a new position in Medpace in the 3rd quarter worth approximately $1,013,000. Jupiter Asset Management Ltd. acquired a new position in Medpace in the 3rd quarter worth approximately $15,312,000. Finally, Coldstream Capital Management Inc. acquired a new position in Medpace in the 2nd quarter worth approximately $218,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 0.7 %

MEDP stock opened at $324.21 on Tuesday. Medpace Holdings, Inc. has a 12-month low of $167.00 and a 12-month high of $331.10. The company has a market cap of $9.95 billion, a price-to-earnings ratio of 37.96 and a beta of 1.29. The company has a 50 day moving average of $298.50 and a two-hundred day moving average of $273.53.

Medpace (NASDAQ:MEDPGet Free Report) last released its quarterly earnings results on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.24. The business had revenue of $498.40 million for the quarter, compared to the consensus estimate of $498.72 million. Medpace had a net margin of 15.33% and a return on equity of 68.48%. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.12 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 8.65 EPS for the current year.

Insider Activity

In related news, VP Susan E. Burwig sold 10,391 shares of Medpace stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $304.15, for a total value of $3,160,422.65. Following the transaction, the vice president now owns 17,292 shares in the company, valued at approximately $5,259,361.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Medpace news, major shareholder Medpace Investors, Llc sold 33,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $283.42, for a total value of $9,352,860.00. Following the sale, the insider now directly owns 5,856,947 shares in the company, valued at approximately $1,659,975,918.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 10,391 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $304.15, for a total transaction of $3,160,422.65. Following the completion of the sale, the vice president now owns 17,292 shares in the company, valued at $5,259,361.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 185,391 shares of company stock worth $51,630,381. 25.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird increased their target price on shares of Medpace from $302.00 to $312.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 17th.

View Our Latest Research Report on Medpace

About Medpace

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Read More

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.